Knuff & Co LLC Reduces Stock Position in DexCom, Inc. (NASDAQ:DXCM)

Knuff & Co LLC lessened its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 8.8% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 30,318 shares of the medical device company’s stock after selling 2,938 shares during the quarter. DexCom comprises about 1.1% of Knuff & Co LLC’s investment portfolio, making the stock its 23rd biggest holding. Knuff & Co LLC’s holdings in DexCom were worth $3,437,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Team Hewins LLC raised its position in shares of DexCom by 3.4% during the first quarter. Team Hewins LLC now owns 2,555 shares of the medical device company’s stock valued at $354,000 after buying an additional 83 shares during the last quarter. Bleakley Financial Group LLC raised its position in shares of DexCom by 1.3% during the first quarter. Bleakley Financial Group LLC now owns 6,856 shares of the medical device company’s stock valued at $951,000 after buying an additional 87 shares during the last quarter. Capital Insight Partners LLC raised its position in shares of DexCom by 2.5% during the second quarter. Capital Insight Partners LLC now owns 3,690 shares of the medical device company’s stock valued at $418,000 after buying an additional 90 shares during the last quarter. D Orazio & Associates Inc. increased its position in DexCom by 0.8% in the fourth quarter. D Orazio & Associates Inc. now owns 12,366 shares of the medical device company’s stock worth $1,534,000 after purchasing an additional 93 shares during the last quarter. Finally, Gulf International Bank UK Ltd increased its position in DexCom by 0.3% in the first quarter. Gulf International Bank UK Ltd now owns 32,075 shares of the medical device company’s stock worth $4,448,000 after purchasing an additional 93 shares during the last quarter. Hedge funds and other institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the transaction, the executive vice president now directly owns 66,249 shares in the company, valued at $4,607,617.95. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, EVP Sadie Stern sold 427 shares of the stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $115.05, for a total transaction of $49,126.35. Following the transaction, the executive vice president now owns 75,877 shares in the company, valued at approximately $8,729,648.85. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Michael Jon Brown sold 652 shares of the stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 3,483 shares of company stock worth $369,052. 0.30% of the stock is owned by corporate insiders.

DexCom Trading Down 0.4 %

Shares of DXCM traded down $0.28 during trading hours on Monday, reaching $69.34. 4,614,200 shares of the company traded hands, compared to its average volume of 3,777,724. The firm has a market cap of $27.58 billion, a price-to-earnings ratio of 44.74, a PEG ratio of 2.15 and a beta of 1.16. DexCom, Inc. has a 12-month low of $62.34 and a 12-month high of $142.00. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. The stock’s fifty day moving average price is $90.92 and its 200 day moving average price is $114.55.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. The business had revenue of $1 billion during the quarter, compared to the consensus estimate of $1.04 billion. DexCom had a net margin of 16.95% and a return on equity of 31.41%. The firm’s revenue was up 15.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.34 earnings per share. Sell-side analysts forecast that DexCom, Inc. will post 1.69 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on the stock. StockNews.com cut shares of DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. UBS Group reduced their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research report on Friday, July 26th. Baird R W cut shares of DexCom from a “strong-buy” rating to a “hold” rating in a research report on Friday, July 26th. Oppenheimer reduced their price target on shares of DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Finally, Redburn Atlantic assumed coverage on shares of DexCom in a research report on Thursday, May 30th. They issued a “neutral” rating and a $130.00 price target on the stock. Seven research analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, DexCom presently has an average rating of “Moderate Buy” and a consensus price target of $112.25.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.